Esperion Therapeutics (ESPR) saw its stock price plummet 6.12% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results. The biopharmaceutical company, known for its cholesterol-lowering treatments, reported figures that fell significantly short of analyst expectations.

The company's Q3 net income came in at a loss of $31.333 million, more than double the expected loss of $14.5 million estimated by IBES. Similarly, Esperion's operating income showed a loss of $9.959 million, considerably worse than the anticipated loss of $1.53 million. These disappointing figures appear to be the primary drivers behind the stock's pre-market decline.

Despite the negative bottom line, Esperion reported product sales of $40.659 million for the quarter. However, this was overshadowed by operating expenses of $97.268 million, highlighting the company's ongoing struggle with cost management. The resulting basic earnings per share (EPS) stood at -$0.16, further underscoring the company's financial challenges. As investors digest these results, the market reaction suggests growing concerns about Esperion's path to profitability and its ability to manage expenses effectively in the competitive pharmaceutical landscape.